Medtech M&A Is Clearing Out the Public-Market Middle

On July 27, American Industrial Partners completed its $1.27 billion acquisition of Avanos Medical, taking the pain management and specialty nutrition company private. Two days later, MIMEDX announced an agreement to acquire Sanara MedTech for approximately $350 million, combining two public wound care businesses.

One was a private equity buyout. The other was consolidation between two smaller public companies. Together, they point to another development in medtech M&A: remaining independent may be getting harder to justify for companies caught between startup scale and large-cap status.

Medtech M&A Activity Is Adding Up

In May, we described the medtech M&A environment as active but not yet a boom. Since then, the pace tracked by Compass AI suggests more of the conditions for an acceleration are falling into place.

Between May 1 and July 30, Compass AI recorded 13 medtech M&A transactions. Among the disclosed deals were Roche’s $1.05 billion acquisition of PathAI, Medtronic’s $650 million SPR Therapeutics deal, MIMEDX’s approximately $350 million Sanara transaction, Resmed’s $340 million acquisition of Noctrix Health, Olympus’ $270 million BioProtect deal, Artivion’s $175 million Endospan acquisition, and Zimmer Biomet’s iovera° transaction at $70 million upfront.

Another six transactions were announced or completed without disclosed values. Include the Avanos take-private, and approximately $4 billion in medtech has changed hands or been committed in a single quarter.

But Avanos and Sanara are particularly revealing.

AIP agreed in April to acquire Avanos for $25.00 per share in cash, valuing the company at approximately $1.272 billion. The transaction closed July 27, taking Avanos private and ending its NYSE listing.

The Sanara transaction follows a different playbook. MIMEDX agreed to acquire Sanara for approximately $35.00 per share through a combination of cash and MIMEDX stock, representing a 46% premium to Sanara’s 30-day average. The approximately $350 million deal is built around scale, cost efficiencies, and a broader wound care and surgical portfolio. The combined business expects 2027 revenue comfortably above $400 million at a 20%-plus adjusted EBITDA margin.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/medtech-ma-is-clearing-out-the-public-market-middle